TPG Sells Par Pharmaceutical to Endo International for $8.05 Billion
Ropes & Gray advised Par Pharmaceutical Holdings, Inc. on its definitive agreement to be acquired by Endo International plc in a transaction valued at $8.05 billion, including assumption of Par debt. Dublin, Ireland-based Endo, which makes branded and generic pharmaceutical products, will acquire Par from private equity firm TPG.
Announced May 18, the transaction is expected to close in the second half of 2015 and is subject to regulatory approval in the U.S., as well as other customary closing conditions.
The Ropes & Gray team included private equity partners William Shields and Michael Roh (both of Boston); securities & public companies partner Julie Jones (Boston); antitrust partner Michael McFalls (Washington, D.C.); tax partner David Saltzman (Boston); and finance partners Jay Kim and Alexander Zeltser (both of New York).